ArticleScientific reports2025
The dynamic states of hepatitis B virus capsid monomers under the impact of different class of capsid-assembly modulators.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- New Developments in the Treatment of Hepatitis B Virus Infection.Gastroenterology & hepatology · 2026Article
- Article
- All-atom molecular dynamics simulation of Cyclophilin A in complex with Sanglifehrin A.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) remains a global health challenge. Capsid assembly modulators (CAMs) represent a promising class of antiviral agents that disrupt HBV core antigen (HBcAg) function. Understanding the structural and dynamic impact of CAMs on HBcAg is crucial for the development of next-generation antiviral therapies. This study employed molecular dynamics (MD) simulations to evaluate the conformational behavior of capsid monomers in unbound and ligand-bound states. Different classes of CAMs, Heteroaryldihydropyrimidine (HAP), Sulfamoylbenzamide (SBA), and Ciclopirox, were analyzed to assess their impact on HBcAg stability, flexibility, and interaction energy. RMSD analysis revealed that HAP binding stabilized HBcAg, reducing backbone fluctuations, whereas SBA and PPA increased HBcAg flexibility. RMSF calculations demonstrated that CAM interactions influenced loop and terminal region dynamics. PCA suggested ligand-specific alterations in HBcAg's essential motions, with Sulfamoylbenzamide inducing the highest variance. Salt bridge analysis indicated that Ciclopirox formed the strongest electrostatic interactions, stabilizing its binding. DSSP secondary structure analysis showed that CAMs disrupted α-helical content, with Sulfamoylbenzamide and Ciclopirox exhibiting the most pronounced structural rearrangements. This study provides novel insights into CAM-induced conformational changes in HBcAg. While HAP stabilizes the core protein, SBA and Ciclopirox increase flexibility, potentially leading to misassembled or destabilized capsids. These findings contribute to the rational design of CAM-based antiviral therapies and highlight key structural determinants for future drug optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.